Focus Partners Wealth Purchases 64,548 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Focus Partners Wealth lifted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 431.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 79,499 shares of the company's stock after buying an additional 64,548 shares during the period. Focus Partners Wealth's holdings in Takeda Pharmaceutical were worth $1,054,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. QRG Capital Management Inc. increased its holdings in shares of Takeda Pharmaceutical by 16.8% during the fourth quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock worth $4,364,000 after buying an additional 47,490 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Takeda Pharmaceutical by 48.6% during the fourth quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock worth $600,000 after buying an additional 14,831 shares in the last quarter. US Bancorp DE increased its holdings in shares of Takeda Pharmaceutical by 21.2% during the fourth quarter. US Bancorp DE now owns 124,332 shares of the company's stock worth $1,646,000 after buying an additional 21,744 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Takeda Pharmaceutical by 27.0% in the fourth quarter. Blue Trust Inc. now owns 14,430 shares of the company's stock worth $205,000 after purchasing an additional 3,071 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Takeda Pharmaceutical by 60.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock worth $2,409,000 after purchasing an additional 68,200 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 1.1%

Shares of Takeda Pharmaceutical stock traded up $0.17 during trading on Friday, hitting $14.58. The company's stock had a trading volume of 1,991,062 shares, compared to its average volume of 1,927,683. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.43. The stock has a market cap of $46.38 billion, a price-to-earnings ratio of 36.44, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The stock has a 50-day moving average price of $14.69 and a two-hundred day moving average price of $14.01.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The business had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. Equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.